Ethosuximide
Brand: Zarontin (US/EU) / Emeside (UK) / Ethosuximide (IN/BD)
Anticonvulsant
T-type calcium channel blocker
Chemistry
| PubChem |
CID: 3291 |
Structure
Pharmacokinetics
| Half-life | 60 hours |
| Bioavailability | 100 % (approx) |
| Protein Binding | 0 % |
| Volume of Distribution | 0.7 L/kg (approx) |
| Clearance Route | hepatic |
| Active Metabolites | uncertain |
| Notes | Mostly hepatic metabolism; therapeutic range typically 40–100 µg/mL; titrate to clinical response. |
⚠️ Safety & Warnings
Severity: Moderate
Adverse Effects:
GI upset, nausea, lethargy, headache; rare blood dyscrasias, SJS
Contraindications:
Hypersensitivity to succinimides
Precautions:
Monitor CBC and for rash; caution in hepatic/renal impairment.